178 related articles for article (PubMed ID: 32646966)
1. The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma.
Buckarma EH; Werneburg NW; Conboy CB; Kabashima A; O'Brien DR; Wang C; Ilyas SI; Smoot RL
Mol Cancer Res; 2020 Oct; 18(10):1574-1588. PubMed ID: 32646966
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.
Smoot RL; Werneburg NW; Sugihara T; Hernandez MC; Yang L; Mehner C; Graham RP; Bronk SF; Truty MJ; Gores GJ
J Cell Biochem; 2018 Jan; 119(1):824-836. PubMed ID: 28661054
[TBL] [Abstract][Full Text] [Related]
3. Tumorigenic role of YAP in hepatocellular carcinogenesis is involved in SHP2 whose function is different in vitro and in vivo.
Kim MK; Park JY; Kang YN
Pathol Res Pract; 2018 Jul; 214(7):1031-1039. PubMed ID: 29699904
[TBL] [Abstract][Full Text] [Related]
4. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function.
Tsutsumi R; Masoudi M; Takahashi A; Fujii Y; Hayashi T; Kikuchi I; Satou Y; Taira M; Hatakeyama M
Dev Cell; 2013 Sep; 26(6):658-65. PubMed ID: 24035415
[TBL] [Abstract][Full Text] [Related]
5. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
Sugihara T; Werneburg NW; Hernandez MC; Yang L; Kabashima A; Hirsova P; Yohanathan L; Sosa C; Truty MJ; Vasmatzis G; Gores GJ; Smoot RL
Mol Cancer Res; 2018 Oct; 16(10):1556-1567. PubMed ID: 29903769
[TBL] [Abstract][Full Text] [Related]
6. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
Conboy CB; Yonkus JA; Buckarma EH; Mun DG; Werneburg NW; Watkins RD; Alva-Ruiz R; Tomlinson JL; Guo Y; Wang J; O'Brien D; McCabe CE; Jessen E; Graham RP; Buijsman RC; Vu D; de Man J; Ilyas SI; Truty MJ; Borad M; Pandey A; Gores GJ; Smoot RL
J Hepatol; 2023 Jan; 78(1):142-152. PubMed ID: 36162702
[TBL] [Abstract][Full Text] [Related]
7. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
[TBL] [Abstract][Full Text] [Related]
8. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
[TBL] [Abstract][Full Text] [Related]
9. YAP and the Hippo pathway in cholangiocarcinoma.
Sugihara T; Isomoto H; Gores G; Smoot R
J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
[TBL] [Abstract][Full Text] [Related]
10.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
11. SHP2 inhibition enhances Yes-associated protein-mediated liver regeneration in murine partial hepatectomy models.
Watkins RD; Buckarma EH; Tomlinson JL; McCabe CE; Yonkus JA; Werneburg NW; Bayer RL; Starlinger PP; Robertson KD; Wang C; Gores GJ; Smoot RL
JCI Insight; 2022 Aug; 7(15):. PubMed ID: 35763355
[TBL] [Abstract][Full Text] [Related]
12. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
[TBL] [Abstract][Full Text] [Related]
13. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
14. Alternative splicing reverses the cell-intrinsic and cell-extrinsic pro-oncogenic potentials of YAP1.
Ben C; Wu X; Takahashi-Kanemitsu A; Knight CT; Hayashi T; Hatakeyama M
J Biol Chem; 2020 Oct; 295(41):13965-13980. PubMed ID: 32763976
[TBL] [Abstract][Full Text] [Related]
15. Harmine alleviates atherogenesis by inhibiting disturbed flow-mediated endothelial activation via protein tyrosine phosphatase PTPN14 and YAP.
Yang Y; Ma Q; Li Z; Wang H; Zhang C; Liu Y; Li B; Wang Y; Cui Q; Xue F; Ai D; Zhu Y; He J
Br J Pharmacol; 2021 Apr; 178(7):1524-1540. PubMed ID: 33474722
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis.
Bunda S; Burrell K; Heir P; Zeng L; Alamsahebpour A; Kano Y; Raught B; Zhang ZY; Zadeh G; Ohh M
Nat Commun; 2015 Nov; 6():8859. PubMed ID: 26617336
[TBL] [Abstract][Full Text] [Related]
17. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Lin L; Sabnis AJ; Chan E; Olivas V; Cade L; Pazarentzos E; Asthana S; Neel D; Yan JJ; Lu X; Pham L; Wang MM; Karachaliou N; Cao MG; Manzano JL; Ramirez JL; Torres JM; Buttitta F; Rudin CM; Collisson EA; Algazi A; Robinson E; Osman I; Muñoz-Couselo E; Cortes J; Frederick DT; Cooper ZA; McMahon M; Marchetti A; Rosell R; Flaherty KT; Wargo JA; Bivona TG
Nat Genet; 2015 Mar; 47(3):250-6. PubMed ID: 25665005
[TBL] [Abstract][Full Text] [Related]
18. Nonreceptor tyrosine phosphatase 14 promotes proliferation and migration through regulating phosphorylation of YAP of Hippo signaling pathway in gastric cancer cells.
Han X; Sun T; Hong J; Wei R; Dong Y; Huang D; Chen J; Ren X; Zhou H; Tian W; Jia Y
J Cell Biochem; 2019 Oct; 120(10):17723-17730. PubMed ID: 31168824
[TBL] [Abstract][Full Text] [Related]
19. Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
Day EK; Zhong Q; Purow B; Lazzara MJ
Cancer Res; 2021 Apr; 81(8):2056-2070. PubMed ID: 33574084
[TBL] [Abstract][Full Text] [Related]
20. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
